{"prompt": "['2017N330177_04', 'CONFIDENTIAL', '-', '205678', '12.6. Appendix 6: Genetics', '125', '12.7.', 'Appendix 7: Liver Safety: Required Actions and Follow-up', 'Assessments and Study Treatment Rechallenge Guidelines', '126', '12.7.1. Liver Safety Drug Restart or Re-Challenge Guidelines', '128', '12.7.1.1. Re-challenge Following Liver Stopping Events', 'that are Possibly Related to Study Treatment', '128', '12.7.1.2.', 'Re-challenge Following Transient Liver', 'Stopping Events Not Related to Study', 'Treatment', '130', '12.7.2. References', '131', '12.8. Appendix 8: ECOG Performance Status', '132', '12.9.', 'Appendix 9: GSK Corneal Event Severity Scale and Mitigation', 'Strategy for GSK2857916 Treatment-Related Corneal Events', '133', '12.10. Appendix 10: Modified Diet in Renal Disease (MDRD) Formula', '136', '12.11. Appendix 11: Protocol Amendment History', '137', '12.12. Appendix 12: Statistical Considerations for Section 10.5.9.2', 'Additional Comparative Futility Stopping Rule Based on Bayesian', 'Approach', '152', 'LIST OF TABLES', 'PAGE', 'Table 1', 'Schedule of Activities - Screening Assessments', '21', 'Table 2', 'Schedule of Activities - On Study Assessments', '23', 'Table 3', 'Schedule of Activities: End of Treatment (EOT) and Follow-Up', 'Assessments', '29', 'Table 4', 'Ocular Sub-Study Schedule of Activities (Selected Sites Only)', '32', 'Table 5', 'Risk Assessment and Mitigation Strategy', '38', 'Table 6', 'Objectives and Endpoints for Study 205678 - GSK2857916 in', 'RRMM Participants Previously Treated with an Anti-CD38', 'Antibody', '41', 'Table 7', 'Summary of Investigator-Assessed Best Response (with', 'Confirmation; Study BMA117159 Part 1)', '49', 'Table 8', 'Summary of Predicted Mean Response and Mean >Grade 2', 'Corneal Event* and 95% Credible Intervals (Parts 1 and 2, Study', 'BMA117159)', '51', 'Table 9', 'Criteria for Determining Adequate Organ System Function', '52', 'Table 10', 'Permitted Dose Reductions', '57', 'Table 11', 'Dose Modification Guidelines for GSK2857916-Related Adverse', 'Events', '59', '9']['2017N330177_04', 'CONFIDENTIAL', '205678', 'Table 12', 'General Dose Modification and Management Guidelines for', 'Drug- related Adverse Events Not Otherwise Specifieda', '60', 'Table 13', 'Dose Modification Guidelines for GSK2857916 Treatment-', 'Related Corneal Events', '61', 'Table 14', 'List of Clinical Laboratory Tests', '73', 'Table 15', 'Statistical Power Scenarios', '91', 'Table 16', 'Analysis Populations Defined for the Study', '91', 'Table 17', 'Statistical Analysis Methods for Efficacy Endpoints', '92', 'Table 18', 'Statistical Analysis Methods for Safety Endpoints', '94', 'Table 19', 'Probabilities of Crossing Boundaries at the Interim or Final ORR', 'Analysis based on Group Sequential Design', '98', 'Table 20', 'Probabilities of Stopping for Futility at the Interim or Claiming', 'Efficacy at the Final ORR Analysis based on Both Futility Rules', '98', 'Table 21', 'Prophylactic Measures for Corneal Events Associated with', 'GSK2857916 a, b', '134', 'Table 22', 'GSK Scale for Corneal Events Associated with GSK2857916a', '134', 'Table 23', 'Guidance on GSK Scale Grading Based on Changes in Visual', 'Acuity', '135', 'Table 24', 'Posterior Probabilities of (Arm 1 Response Rate > Arm 2', 'Response Rate) at Interim Analyses', '153', 'Table 25', 'Scenarios of Simulation Studies to Evaluate Probabilities of', 'Stopping for Futility', '154', 'LIST OF FIGURES', 'PAGE', 'Figure 1', 'Study 205678 Schematic', '44', 'Figure 2', 'Fitted Dose-Response Plot for ORR and Grade 2 Corneal', 'Event Rate', '50', 'Figure 3', 'Liver Chemistry Stopping Criteria - Liver Stopping Event', 'Algorithm', '68', 'Figure 4', 'Ocular prophylaxis schematic', '81', '10']\n\n###\n\n", "completion": "END"}